Wal-Mart Woes Slow ...
Health Care: Drugs
Verastem Inc (VSTM: NASDAQ)
$9.19 -0.25 | -2.65%
05/17/13 - 04:00 PM ET
53.34K / 19.80K
Vol / Avg. Vol:9.42 / 9.44
Open / Prev. Close:9.03 - 9.67
Today's Range:6.25 - 12.00
52 Wk Range:7.39%
Performance YTD:TheStreet Rating:
Portfolios with VSTM
- Portfolio NameUser Type
Latest VSTM Headlines from TheStreet
- Eli Lilly, Verastem and the Defenders of Shareholder Value 07.16.12 | 07:07 am
- On Nowruz, Reviewing Drug Stock Picks 03.26.12 | 07:03 am
- Verastem and the Broken Wall Street Research Model 03.12.12 | 07:03 am
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
- Verastem IPO Looks Like Risky Bet 01.26.12 | 07:01 am
- IPO: Unproven Verastem
01.26.12 | 05:01 am
Press Releases for VSTM
- Verastem To Present At Upcoming Conferences - Business Wire 03.28.13 | 04:03 pm
- Verastem Reports Year-End 2012 Financial Results - Business Wire 03.27.13 | 06:03 am
- Verastem Announces Timing For Year-End 2012 Financial Results, Webcast And Conference Call - Business Wire 03.13.13 | 07:03 am
- Stephen Sherwin, M.D., Joins Verastem Board Of Directors - Business Wire 03.06.13 | 07:03 am
- Verastem Cofounders To Present At MIT Technology Breakfast On Breakthrough Discoveries In Cancer Stem Cells - Business Wire 02.27.13 | 07:02 am
- Verastem To Present At Upcoming Conferences - Business Wire 02.26.13 | 04:02 pm
- Verastem To Present At Keystone Symposia On PI3 Kinase - Business Wire 02.20.13 | 07:02 am
- Verastem Files For Orphan Disease Status For VS-6063 In Mesothelioma - Business Wire 02.14.13 | 07:02 am
- Scientific Data On PI3K/mTOR Inhibitor VS-5584 Published In Molecular Cancer Therapeutics - Business Wire 02.06.13 | 07:02 am
- Verastem Initiates Phase 1/1b Clinical Trial Of VS-6063 Plus Paclitaxel For Patients With Ovarian Cancer - Business Wire 02.05.13 | 07:02 am
Partner Headlines for VSTM
